// App-Quantinova.ai

8558 : A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

Researchers

Presenter

  • Dean Anthony Fennell

Principal Investigators

  • Seid Mohammed

  • Amy Branson

  • Alastair Greystoke

  • Sam Moody

  • Margaret Hutka

  • Alan G. Dawson

  • Liz Darlison

  • Molly Scotland

  • Vina Bhundia

  • Amrita Bajaj

  • Bruno Morgan

  • Adrian Nicholson

  • Cassandra Brookes

  • Aarti Gaba

  • Peter Wells-Jordan

  • Catherine Jane Richards

  • Anne Thomas

Medical Centers

  • University of Leicester and University Hospitals of Leicester, Leicester, United Kingdom

  • University of Leeds, Leeds, United Kingdom

  • Leicester Clinical Trials Unit, University of Leicester, Leicester, United Kingdom

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mesothelioma

Biomarkers

  • BRCA1-associated protein 1

  • Breast cancer type 1 susceptibility protein

  • Programmed death-ligand 1

Drug/Treatment

  • Abemaciclib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03654833

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved